Healthcare Industry News: Reliant Pharmaceuticals
News Release - February 18, 2014
Iroko Pharmaceuticals Makes Strategic Additions to the Company’s Board of DirectorsCompany appoints two pharmaceutical marketing executives as it commercializes its lower dose NSAID portfolio
PHILADELPHIA--(Healthcare Sales & Marketing Network)--Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced the appointment of Bradley T. Sheares, Ph.D. and Louis Vollmer to the board of directors of Iroko Pharmaceuticals Inc. Dr. Sheares and Mr. Vollmer bring more than 50 years of combined pharmaceutical marketing experience, having held senior leadership positions at Reliant Pharmaceuticals, Inc., Merck & Co., DuPont Pharmaceuticals, and Endo Pharmaceuticals Inc.
“On behalf of our entire Iroko team, I want to welcome Dr. Sheares and Mr. Vollmer to our board,” said Osagie Imasogie, Executive Chairman of the Board, Iroko Pharmaceuticals. “These seasoned and successful senior pharmaceutical marketing executives are joining Iroko at an exciting time, as we are launching our first new product, Zorvolex™, and continue to work towards developing and commercializing our franchise of lower dose NSAIDs using SoluMatrix Fine Particle Technology™.”
Dr. Sheares served as Chief Executive Officer of Reliant Pharmaceuticals, Inc., from January 2007 through its acquisition by GlaxoSmithKline plc in December 2007. Prior to joining Reliant, he served as President of U.S. Human Health for Merck & Co. from 2001 until 2006. As a member of Merck’s management committee, Dr. Sheares had responsibility for formulating global business strategies, operations management and the development and implementation of corporate policies. He is also a director of Honeywell International, The Progressive Corporation, Covance Inc., and Henry Schein Inc. Dr. Sheares graduated summa cum laude with a bachelor's degree in chemistry from Fisk University and received his Ph.D. in biochemistry from Purdue University.
“Iroko is poised for success with an extensive late-stage pipeline of lower dose NSAIDs and is well on its way to executing the company’s first product launch,” said Dr. Sheares. “I’m excited to be joining a company that has already started to achieve its clearly defined vision.”
Mr. Vollmer is a senior pharmaceutical industry executive, with experience in chemistry and business. He was a co-founder of DuPont Pharmaceutical’s generics business and one of the partners responsible for the subsequent $300 million management buy-out of that and other related businesses which eventually became Endo Pharmaceuticals Inc. As the Founding Executive Vice President, Sales and Marketing, for Endo, Mr. Vollmer provided leadership in developing and implementing the strategies required to market Endo’s re-protected and re-positioned multi-source and generic products into the marketplace. Prior to founding Endo, he was employed by DuPont Merck for 19 years, holding several positions of increasing responsibility, including Vice President of Sales & Marketing for DuPont Multi-Source Products with responsibility for over 12 branded products. During his time with DuPont Merck and Endo, he received a number of corporate awards, including being inducted in 1991 into the DuPont Marketing Research Hall of Fame. He holds a Bachelor of Arts degree in biology and chemistry from the University of Delaware.
“I look forward to bringing my expertise in launching pain management products to Iroko,” said Mr. Vollmer. “I am excited to be joining a team that is on the front lines of developing innovative solutions to fill unmet needs in analgesia, an area to which I’ve dedicated much of my career.”
About Iroko Pharmaceuticals, LLC
Iroko is a global specialty pharmaceutical company, based in Philadelphia, dedicated to advancing the science of analgesia. The company develops and globally commercializes pharmaceutical products. In addition to the Iroko products that are marketed worldwide, the company has a robust pipeline of investigational lower dose NSAID products being developed using iCeutica Inc.’s proprietary SoluMatrix Fine Particle Technology™. For more information, visit www.iroko.com.
SoluMatrix Fine Particle Technology™ is a trademark of iCeutica Inc., and is licensed to Iroko for exclusive use in NSAIDs.
Source: Iroko Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.